Targeting gut T cell Ca2+ release-activated Ca2+ channels inhibits T cell cytokine production and T-box transcription factor T-bet in inflammatory bowel disease

Antonio Di Sabatino, Laura Rovedatti, Rejbinder Kaur, Jonathan P. Spencer, Jon T. Brown, Valerie D. Morisset, Paolo Biancheri, Nicholas A B Leakey, Jonathan I. Wilde, Laurie Scott, Gino R. Corazza, Kevin Lee, Neel Sengupta, Charles H. Knowles, Martin J. Gunthorpe, Peter G. McLean, Thomas T. MacDonald, Laurens Kruidenier

Research output: Contribution to journalArticle

Abstract

Prolonged Ca2+ entry through Ca2+ release-activated Ca2+ (CRAC) channels is crucial in activating the Ca 2+-sensitive transcription factor NFAT, which is responsible for directing T cell proliferation and cytokine gene expression. To establish whether targeting CRAC might counteract intestinal inflammation, we evaluated the in vitro effect of a selective CRAC inhibitor on T cell cytokine production and T-bet expression by lamina propria mononuclear cells (LPMC) and biopsy specimens from inflammatory bowel disease (IBD) patients. The inhibitory activity of the CRAC blocker was investigated through patch-clamp experiments on rat basophilic leukemia cells and fluorometric imaging plate reader intracellular Ca2+ assays using thapsigargin-stimulated Jurkat T cells and its detailed selectivity profile defined using a range of in vitro radioligand binding and functional assays. Anti-CD3/CD28-stimulated LPMC and biopsy specimens from 51 patients with IBD were cultured with a range of CRAC inhibitor concentrations (0.01-10 μM). IFN-γ, IL-2, IL-8, and IL-17 were analyzed by ELISA. T-bet was determined by immunoblotting. We found that the CRAC blocker concentration-dependently inhibited CRAC current in rat basophilic leukemia cells and thapsigargin-induced Ca2+ influx in Jurkat T cells. A concentration-dependent reduction in T-bet expression and production of IFN-γ, IL-2, IL-17, but not IL-8, was observed in IBD LPMC and biopsy specimens treated with the CRAC inhibitor. In conclusion, we provide evidence that the suppression of CRAC channel function may dampen the increased T cell response in the inflamed gut, thus suggesting a promising role for CRAC inhibitor drugs in the therapeutic management of patients with IBD.

Original languageEnglish
Pages (from-to)3454-3462
Number of pages9
JournalJournal of Immunology
Volume183
Issue number5
DOIs
Publication statusPublished - Sep 1 2009

ASJC Scopus subject areas

  • Immunology
  • Medicine(all)

Fingerprint Dive into the research topics of 'Targeting gut T cell Ca<sup>2+</sup> release-activated Ca<sup>2+</sup> channels inhibits T cell cytokine production and T-box transcription factor T-bet in inflammatory bowel disease'. Together they form a unique fingerprint.

  • Cite this

    Di Sabatino, A., Rovedatti, L., Kaur, R., Spencer, J. P., Brown, J. T., Morisset, V. D., Biancheri, P., Leakey, N. A. B., Wilde, J. I., Scott, L., Corazza, G. R., Lee, K., Sengupta, N., Knowles, C. H., Gunthorpe, M. J., McLean, P. G., MacDonald, T. T., & Kruidenier, L. (2009). Targeting gut T cell Ca2+ release-activated Ca2+ channels inhibits T cell cytokine production and T-box transcription factor T-bet in inflammatory bowel disease. Journal of Immunology, 183(5), 3454-3462. https://doi.org/10.4049/jimmunol.0802887